Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell-cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The book is based on the Cancers journal Special Issue entitled “Immunotherapy, Tumor Microenvironment and Survival Signaling", and focuses on important problems concerning tumors and tumor microenvironment interactions, as well as novel immunotherapies such as CAR-T cell therapy. Immunotherapies have recently shown remarkable results in the treatment of cancer patients. However, there are still many questions that remain to be solved in regards to more effective therapies, such as the tumor heterogeneous profile, tumor microenvironment, and tumor survival epigenetic and genetic pathways, all of which make patients resistant to the presently available treatments for cancer. This book demonstrates different approaches to overcome the challenges faced by immunotherapies due to suppressive tumor microenvironments. This book includes 18 papers that can be divided into three chapters: 1. novel immunotherapies; 2. targeting tumor microenvironment and novel approaches; 3. targeting tumors and tumor microenvironment in different types of cancer.

Medicine --- Clinical & internal medicine --- Autophagy --- colorectal cancer --- immunotherapy --- tumor stroma --- tumor microenvironment --- immune checkpoint inhibitors --- chemotherapy --- tyrosine kinase inhibitors --- angiogenesis --- check point inhibitors --- programmed cell death protein 1 --- programmed cell death 1 ligand 1 --- cardiotoxicity --- lung metastasis --- CAR-T --- hypoxia --- tumor --- microenvironment --- CD19 --- BCMA --- cancer --- melanoma --- immune escape --- antigen loss --- chimeric antigen receptor --- electroporation --- lentivirus --- lentiviral transduction --- macrophages --- leukemia cells --- lytic peptides --- targeted therapy --- dendritic cells --- pathogenesis --- risk factors --- breast cancer --- resistance --- checkpoint --- targeted treatment --- personalized medicine --- pediatric solid tumors --- chimeric antigen receptors --- cancer vaccines --- oncolytic viral therapy --- immunomodulation --- DCLK1 --- tumor stem cells --- clonogenicity --- mitochondria --- mitochondrial transfer --- tunneling nanotubes --- triple-negative breast cancer --- immune checkpoint inhibitor --- combination therapy --- cancer nanomedicine --- tumor antigens --- cancer metabolism --- cancer immunotherapy --- nanoparticles --- immunotherapeutic agent --- immunomodulators --- tuft cells --- cancer stem cells --- immunotherapies --- myeloid-derived suppressor cells --- regulatory T cells --- crosstalk --- tumor immune evasion --- cell–cell contact --- β2 integrins --- CD18 --- CD11 --- CAR-T cells --- CD37 --- cell therapy --- tumor antigen --- lymphoma --- CAR macrophage --- CAR T cell --- solid tumors --- immunometabolism --- miRNA --- immunogenic cell death --- n/a --- cell-cell contact

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book summarizes the importance of peptide–membrane interactions, mostly aiming at developing new therapeutic approaches. The experimental and computational methodologies used to investigate such interactions reveal the evolution of existing biophysical methodologies, shedding some light on potential applications of peptides, as well as on the improvement of their design. Understanding the determinants for peptide–membrane interactions may also improve the knowledge of membrane functions such as the membrane transport, fusion, and signaling processes, contributing to the development of new agents for highly relevant applications ranging from disease treatment to food technology.

tachyplesin --- host defense peptide --- anticancer --- antimicrobial --- antibiofilm --- peptide-membrane interaction --- structure-activity --- model membranes --- nuclear magnetic resonance solution structure --- accelerated molecular dynamics --- alamethicin --- membrane --- peptaibol --- cell-penetrating peptide --- peptide–lipid interaction --- lipid model systems --- molecular dynamics --- NMR --- membrane biophysics --- antimicrobial peptides --- non-lytic peptides --- bacterial membranes --- calcium hydroxide --- chemokine --- human beta defensin-3-C15 --- human dental pulp cell --- Streptococcus gordonii lipoprotein --- luffa sponge --- phosphopeptide --- mass spectrometry --- Matrix-assisted laser desorption ionization --- solid-phase extraction --- surface plasmon resonance --- melittin --- liposomes --- peptide–lipid interactions --- anti-microbial peptides --- pore-forming peptides --- ESKAPE pathogens --- Staphylococcus aureus --- KR12 --- LL-37 --- lipopeptide --- critical aggregation concentration --- CD spectroscopy --- biofilm --- cytotoxicity --- organisms --- sequence analysis --- machine learning --- feature selection --- sesame protein --- ACE inhibitory peptides --- simulated gastrointestinal digestion --- amino acid sequence --- molecular docking --- chionodracines --- circular dichroism --- membrane affinity --- cell-penetrating peptides --- circular dichroism spectroscopy --- atomic force microscopy --- mycolic acid --- Langmuir monolayer --- drug–peptide conjugates --- metastasis model of B16F10 melanoma --- Pisum sativum defensin 1 (Psd1) --- anti-metastatic activity --- glucosylceramide (GlcCer) --- cyclin F --- anti-inflammatory peptide --- cell permeable peptide --- heparin-binding peptide --- collagen-induced arthritis --- inducible nitric oxide --- interferon gamma --- interleukin-6 --- Enbrel